Navigation Links
CRi Announces Maestro 2, the Next Generation in Vivo Optical Imaging Systems
Date:11/26/2007

WOBURN, Mass., Nov. 26 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) announces the launch of Maestro 2 optical imaging systems in North America. The Maestro 2 received widespread acclaim at the both the recent Society of Molecular Imaging/Academy of Molecular Imaging joint conference for in vivo imaging, and at the Stanford University Small Animal Imaging Workshop as well. Maestro 2, the fully automated version of the award-winning Maestro small animal imaging system, is the ideal optical imaging system for both core imaging facilities and individual laboratories using fluorescence-based imaging methodologies.

Maestro 2 combines the sensitivity and features of the original Maestro in vivo imaging system with advanced animal handling features -- an integrated anesthesia system and temperature controlled stage and imaging chamber. Computer-controlled automation through a new, user-friendly interface provides easy zoom and focus adjustments and a rapid selection of a full range of excitation and emission filters. The Flex(TM) liquid crystal tunable filter (LCTF) provides fast, accurate spectral imaging from 500 to 950 nm, covering the full range of available in vivo fluorophores. The fully automated system allows easy instrument setup and calibration for faster, more accurate results within and between experiments. Maestro 2 provides increased sensitivity, automatic removal of autofluorescence for increase spectral contrast, and improved quantification of experimental results.

The Flex LCTF technology provides more accurate multiplexing capability and better quantification of experimental results. The software includes the Real Component Analysis(TM) (RCA) algorithm for automatic identification of spectral signatures and the Compute Spectra(TM) tool, which automatically separates combined or overlapping spectral signatures, enabling the end-user to build spectral libraries quickly and to rapidly analyze data. Quantitative measurement tools include component segmentation and regions of interest (ROI) analysis. Spatial, temporal and spectral separation of multiple signals are all enabled in the new Maestro 2, resulting in improved detection and quantification of co-localized signals in vivo.

"We are very excited about the Maestro 2 In Vivo Imaging System", says James Mansfield, Director of Multispectral Imaging Systems at CRi. "From its ergonomic design, optimized optics and user-friendly software tools, this system was designed and developed with the customers' needs in mind."

CRi, a Boston-based biomedical imaging company, has provided innovative optical imaging solutions for its customers for more than 20 years. A multidisciplinary team is dedicated to working with academic and commercial customers to provide high-value solutions. CRi provides comprehensive imaging and analysis solutions that enable the user to investigate and characterize biological phenotypes while preserving spatial context. With over 80 patents issued and pending, CRi's solution platforms encompass sub-cellular, cellular and whole animal applications. CRi's innovations are being utilized around the world to enable new breakthroughs in research, health and medicine. For more information visit our website at http://www.cri-inc.com or contact:

David Daniels, Ph.D.

Director of Marketing

CRi

35-B Cabot Road, Woburn, MA 01801 USA

Tel: 1-781-935-9099, extension 149

E-mail: ddaniels@cri-inc.com


'/>"/>
SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... AUSTIN, Texas, March 29, 2017  Vermillion, Inc. ... gynecologic disease, reported on its results for the ... 2016. "2016 marked a pivotal year ... ACOG guideline inclusion, international distribution agreements, major reimbursement ... in network payer agreements. In addition we cleared ...
(Date:3/29/2017)... - Last year,s petition to the White House signed by ... to generate awareness on the importance of new organic medicines and ... market place. ... Earlier this month Health Advance (OTC PINK: HADV ... products, announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March ... International Mexico has been approved as an active member of the Mexican ... protection among distributers and consumers in relationship marketing. This professional organization fosters loyal ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
Breaking Biology News(10 mins):